Novo Nordisk to Launch Wegovy Vial Version in Price War with Eli Lilly
Novo Nordisk A/S (NYSE: NVO) announced plans to launch a vial version of Wegovy (semaglutide), shifting...
NYSE: LLY
Eli Lilly’s Jaypirca Wins NMPA Approval for CLL/SLL Post-BTK Inhibitor Therapy
Eli Lilly and Company (NYSE: LLY) announced that the National Medical Products Administration (NMPA) has approved...
Eli Lilly’s Omvoh Wins NMPA Approval for Crohn’s Disease and Ulcerative Colitis in China
The National Medical Products Administration (NMPA) has approved Eli Lilly and Company’s (NYSE: LLY) Omvoh (mirikizumab),...
Eli Lilly Revenue Surges 45% to $65.2B on Incretin Portfolio Strength
Eli Lilly and Company (NYSE: LLY) reported fourth‑quarter 2025 revenue of USD 19.29 billion, up 43% year‑on‑year (YOY),...
Eli Lilly to Invest $3.5B in Pennsylvania Plant for Retatrutide Production
Eli Lilly (NYSE: LLY) announced plans to invest more than USD 3.5 billion in a new manufacturing facility...
Eli Lilly Mounjaro Fails to Win EU Approval for HFpEF Heart Failure Indication
Eli Lilly (NYSE: LLY) announced that the European Medicines Agency (EMA) drug advisory panel declined to...
Zonsen Peplib Signs Eli Lilly Deal After Novartis Partnership
Zonsen Peplib Biotech Inc., a China‑based polypeptide lead compound developer, announced a collaboration with Eli...
Seamless Therapeutics Partners with Eli Lilly on $1.12B Hearing Loss Recombinase Deal
Seamless Therapeutics, a Germany‑based gene editing company, announced a global strategic research collaboration and license...
Lilly’s Sofetabart Wins FDA Breakthrough Status for Platinum‑Resistant Ovarian Cancer
Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has...
NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development
NVIDIA Corporation and Eli Lilly and Company (NYSE: LLY) announced a first‑of‑its‑kind AI co‑innovation lab to...
InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform
InduPro announced a global strategic collaboration, licensing agreement, and equity investment with Eli Lilly (NYSE:...
Lilly’s Taltz-Zepbound Combo Meets Primary Endpoint in Psoriatic Arthritis
Eli Lilly (NYSE: LLY) announced positive topline results from the TOGETHER‑PsA open‑label Phase 3b trial evaluating...
Novo Nordisk, Lilly Cut China Prices for Wegovy, Mounjaro by Up to 80%
Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) have lowered list prices for their...
Lilly Nears $1 Billion Deal for Ventyx’s IBD Pipeline
Eli Lilly (NYSE: LLY) is in advanced talks to acquire Ventyx Biosciences for more than...
Nimbus Therapeutics Partners with Eli Lilly on $1.3 Billion Obesity Drug Deal
Nimbus Therapeutics announced a multi‑year research collaboration and global exclusive licensing agreement with Eli Lilly...
Lilly Imlunestrant Breast-Cancer EMBER-3 Shows 38% Risk Reduction
Eli Lilly (NYSE: LLY) announced updated results from the Phase III EMBER‑3 clinical trial evaluating its...
Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial
Eli Lilly & Co. (NYSE: LLY) announced positive topline results from the Phase 3 TRIUMPH‑4...
Lilly to Invest Over $6 Billion in Alabama GLP‑1 Manufacturing Hub for Orforglipron
Eli Lilly & Co. (NYSE: LLY) announced plans to invest more than USD 6 billion in a...
MeiraGTx Grants Eli Lilly Worldwide Rights to AAV‑AIPL1 Gene Therapy for LCA4
MeiraGTx Holdings plc (NASDAQ: MGTX) announced a strategic ophthalmology collaboration with Eli Lilly and Company...